It was described for the first time in 2013 after being isolated from different hosts worldwide (North and South America, Europe, Africa, Northeast Asia, and Asia-Pacific).

A.felis is an important emerging agent of invasive aspergillosis in cats, dogs and humans because it is often refractory to aggressive antifungal treatment and its identification implies molecular and morphological techniques.

[3] According to mating-type analysis, Aspergillus felis has a fully functioning reproductive cycle as induction of teleomorphs appears within 7 to 10 days in vitro and there is also ascospore germination.

[3] Among all cases reported, A. felis can give serious different diseases depending on hosts: A.felis causes infection in immunocompetent cats and dogs and immunocompromised patients.

The use of different temperatures seems to be a solution as A. felis is able to grow at 45°C while it has been shown in several studies that A. viridinutans and A. udagawae showed no growth at 45°C.

The gold standard method is using both molecular and morphological techniques[3][7] to avoid misidentification with different species within the same complex which would explain why only a few clinical cases of A. felis in humans have been described so far.

Susceptibilities of several A. felis isolates to amphotericin B, itraconazole, posaconazole, voriconazole, fluconazole, 5-flucytosine, terninafine, caspofungin, anidulafungin and micafungin were assessed in cats.

[3] A case of cranial aspergillosis with A. felis was reported in a 66-year-old male with chronic lymphocytic leukaemia and was successfully managed with voriconazole and surgery followed by maintenance with posaconazole.